Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 10 | $1,250 |
Sells | 98 | $16,178,890 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
18 Dec 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Dec 2023 | Sale | 5,803 | 14.1763 | 82,265 | D |
18 Dec 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Dec 2023 | Sale | 26,732 | 12.9401 | 345,915 | D |
14 Dec 2023 20:59 | GNLX | GENELUX Corp | TYREE JAMES L | Director | 13 Dec 2023 | Sale | 3,347 | 13.7327 | 45,963 | D |
14 Dec 2023 20:59 | GNLX | GENELUX Corp | TYREE JAMES L | Director | 13 Dec 2023 | Sale | 5,653 | 12.9145 | 73,006 | D |
14 Dec 2023 20:58 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 13 Dec 2023 | Sale | 1,927 | 13.9277 | 26,839 | D |
14 Dec 2023 20:58 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 13 Dec 2023 | Sale | 7,073 | 13.2261 | 93,548 | D |
08 Dec 2023 17:57 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 07 Dec 2023 | Sale | 36,800 | 11.8477 | 435,995 | D |
22 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 21 Nov 2023 | Sale | 18,665 | 10.2628 | 191,555 | D |
21 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 17 Nov 2023 | Sale | 3,541 | 13.0386 | 46,170 | D |
21 Nov 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 20 Nov 2023 | Sale | 14,594 | 11.2554 | 164,261 | D |
26 Oct 2023 17:07 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 25 Oct 2023 | Sale | 5,704 | 19.3965 | 110,638 | I |
25 Oct 2023 16:51 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 23 Oct 2023 | Sale | 49,987 | 19.9725 | 998,365 | I |
25 Oct 2023 16:15 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 24 Oct 2023 | Sale | 5,200 | 19.106 | 99,351 | D |
16 Oct 2023 18:39 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 16 Oct 2023 | Sale | 2,452 | 20.5014 | 50,269 | D |
16 Oct 2023 18:39 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 16 Oct 2023 | Sale | 881 | 21.3037 | 18,769 | D |
11 Oct 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 10 Oct 2023 | Sale | 400 | 22.906 | 9,162 | D |
11 Oct 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 10 Oct 2023 | Sale | 4,800 | 21.9374 | 105,300 | D |
10 Oct 2023 16:49 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 05 Oct 2023 | Sale | 13,266 | 24.8861 | 330,139 | I |
10 Oct 2023 16:49 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 05 Oct 2023 | Sale | 985 | 25.4719 | 25,090 | I |
04 Oct 2023 18:43 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 03 Oct 2023 | Sale | 75,690 | 25.4885 | 1,929,225 | I |
29 Sep 2023 16:34 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 28 Sep 2023 | Sale | 2,289 | 24.12 | 55,211 | I |
29 Sep 2023 16:34 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 27 Sep 2023 | Sale | 11,257 | 24.47 | 275,459 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 26 Sep 2023 | Sale | 9,600 | 24.51 | 235,296 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 26 Sep 2023 | Sale | 12,740 | 24.03 | 306,142 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 26 Sep 2023 | Sale | 7,465 | 22.47 | 167,739 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 25 Sep 2023 | Sale | 1,100 | 27.81 | 30,591 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 25 Sep 2023 | Sale | 1,900 | 26.6 | 50,540 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 25 Sep 2023 | Sale | 5,511 | 25.75 | 141,908 | I |
27 Sep 2023 16:33 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 25 Sep 2023 | Sale | 3,947 | 24.82 | 97,965 | I |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 2,203 | 24.4623 | 53,890 | D |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 1,114 | 23.5145 | 26,195 | D |
27 Sep 2023 16:10 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 26 Sep 2023 | Sale | 1,883 | 22.5397 | 42,442 | D |
25 Sep 2023 18:30 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 22 Sep 2023 | Sale | 4,621 | 27.758 | 128,270 | I |
25 Sep 2023 18:30 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 21 Sep 2023 | Sale | 4,678 | 28.819 | 134,815 | I |
25 Sep 2023 18:30 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 22 Sep 2023 | Sale | 4,421 | 26.8837 | 118,853 | I |
25 Sep 2023 18:30 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 21 Sep 2023 | Sale | 2,871 | 27.8868 | 80,063 | I |
21 Sep 2023 16:35 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 20 Sep 2023 | Sale | 6,000 | 27.9643 | 167,786 | D |
21 Sep 2023 16:30 | GNLX | GENELUX Corp | RYDER SEAN | General Counsel | 20 Sep 2023 | Sale | 10,000 | 30 | 300,000 | D |
20 Sep 2023 16:48 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 19 Sep 2023 | Sale | 8,247 | 27.1589 | 223,979 | D |
20 Sep 2023 16:48 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 19 Sep 2023 | Sale | 23,920 | 26.2108 | 626,962 | D |
20 Sep 2023 16:48 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 18 Sep 2023 | Sale | 2,927 | 24.1729 | 70,754 | I |
20 Sep 2023 16:48 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 18 Sep 2023 | Sale | 27,365 | 23.201 | 634,895 | I |
18 Sep 2023 20:12 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 15 Sep 2023 | Sale | 1,088 | 22.3838 | 24,354 | D |
18 Sep 2023 20:12 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 18 Sep 2023 | Sale | 3,334 | 24.99 | 83,317 | D |
18 Sep 2023 20:12 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 15 Sep 2023 | Sale | 2,245 | 21.667 | 48,642 | D |
18 Sep 2023 20:13 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Sep 2023 | Sale | 4,675 | 22.2913 | 104,212 | D |
18 Sep 2023 20:13 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 15 Sep 2023 | Sale | 5,725 | 21.5578 | 123,418 | D |
15 Sep 2023 20:06 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 13 Sep 2023 | Sale | 29,800 | 21.1385 | 629,927 | D |
15 Sep 2023 16:19 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 14 Sep 2023 | Sale | 13,871 | 22.3143 | 309,522 | I |
15 Sep 2023 16:19 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 13 Sep 2023 | Sale | 3,315 | 22.3109 | 73,961 | I |
15 Sep 2023 16:19 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 14 Sep 2023 | Sale | 11,405 | 21.7698 | 248,285 | I |
15 Sep 2023 16:19 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 13 Sep 2023 | Sale | 15,717 | 21.2593 | 334,132 | I |
14 Sep 2023 20:18 | GNLX | GENELUX Corp | SMITHER JOHN W | Director | 13 Sep 2023 | Sale | 900 | 20.78 | 18,702 | D |
13 Sep 2023 19:04 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 12 Sep 2023 | Sale | 13,727 | 22.5057 | 308,936 | I |
13 Sep 2023 19:04 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 12 Sep 2023 | Sale | 6,538 | 21.7545 | 142,231 | I |
13 Sep 2023 19:04 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 11 Sep 2023 | Sale | 23,020 | 22.5524 | 519,156 | I |
13 Sep 2023 19:04 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 11 Sep 2023 | Sale | 9,331 | 21.3852 | 199,545 | I |
11 Sep 2023 19:05 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 08 Sep 2023 | Sale | 2,636 | 24.1852 | 63,752 | I |
11 Sep 2023 19:05 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 08 Sep 2023 | Sale | 8,523 | 23.4857 | 200,169 | I |
11 Sep 2023 19:05 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 08 Sep 2023 | Sale | 13,672 | 22.7773 | 311,411 | I |
11 Sep 2023 19:05 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 07 Sep 2023 | Sale | 2,508 | 25.3395 | 63,551 | I |
11 Sep 2023 19:05 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 07 Sep 2023 | Sale | 9,938 | 24.1212 | 239,716 | I |
13 Sep 2024 18:22 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 13 Sep 2024 | Sale | 33,080 | 2.5679 | 84,946 | I |
13 Sep 2024 18:22 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 12 Sep 2024 | Sale | 31,777 | 2.7294 | 86,732 | I |
12 Sep 2024 20:40 | GNLX | GENELUX Corp | TYREE JAMES L | Director | 11 Sep 2024 | Sale | 1,730 | 2.6005 | 4,499 | D |
11 Sep 2024 18:23 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 11 Sep 2024 | Sale | 31,376 | 2.6207 | 82,227 | I |
11 Sep 2024 18:23 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 10 Sep 2024 | Sale | 20,384 | 2.5109 | 51,182 | I |
11 Sep 2024 18:23 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 09 Sep 2024 | Sale | 23,383 | 2.7028 | 63,200 | I |
06 Sep 2024 17:08 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 03 Sep 2024 | Sale | 42,818 | 2.0929 | 89,614 | I |
30 Aug 2024 19:58 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 30 Aug 2024 | Sale | 142,589 | 2.173 | 309,846 | I |
30 Aug 2024 19:58 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 29 Aug 2024 | Sale | 107,045 | 1.9801 | 211,960 | I |
30 Aug 2024 19:58 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 28 Aug 2024 | Sale | 15,918 | 2.0483 | 32,605 | I |
27 Aug 2024 19:23 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 27 Aug 2024 | Sale | 51,630 | 2.1085 | 108,862 | I |
27 Aug 2024 19:23 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 23 Aug 2024 | Sale | 40,000 | 2.2854 | 91,416 | I |
08 Jul 2024 16:30 | GNLX | GENELUX Corp | RYDER SEAN | General Counsel | 24 Jun 2024 | Sale | 5,496 | 2.12 | 11,652 | D |
08 Jul 2024 16:30 | GNLX | GENELUX Corp | JEWETT CAROLINE | Head of Quality | 24 Jun 2024 | Sale | 4,961 | 2.12 | 10,517 | D |
08 Jul 2024 16:30 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 24 Jun 2024 | Sale | 6,849 | 2.12 | 14,520 | D |
07 Jun 2024 21:45 | GNLX | GENELUX Corp | MIRABELLI MARY | Director | 29 May 2024 | Purchase | 8,000 | 0 | 0 | D |
07 Jun 2024 21:45 | GNLX | GENELUX Corp | THOMAS JOHN | Director | 29 May 2024 | Purchase | 2,500 | 0 | 0 | D |
07 Jun 2024 21:45 | GNLX | GENELUX Corp | SMITHER JOHN W | Director | 29 May 2024 | Purchase | 6,250 | 0 | 0 | D |
07 Jun 2024 21:45 | GNLX | GENELUX Corp | TYREE JAMES L | Director | 29 May 2024 | Purchase | 6,250 | 0 | 0 | D |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | RYDER SEAN | General Counsel | 29 May 2024 | Purchase | 10,000 | 0 | 0 | D |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | ZAK LOURIE S. | Chief Financial Officer | 29 May 2024 | Purchase | 31,250 | 0 | 0 | D |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | SMALLING RALPH | Head of Regulatory | 29 May 2024 | Purchase | 1,250 | 0 | 0 | D |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | ZINDRICK THOMAS | President and CEO | 29 May 2024 | Purchase | 200,000 | 0 | 0 | I |
07 Jun 2024 21:40 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 29 May 2024 | Purchase | 2,500 | 0 | 0 | D |
15 May 2024 17:59 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 15 May 2024 | Sale | 17,094 | 3.6635 | 62,624 | I |
15 May 2024 17:59 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 14 May 2024 | Sale | 15,426 | 3.5832 | 55,274 | I |
15 May 2024 17:59 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 13 May 2024 | Sale | 3,446 | 3.6211 | 12,478 | I |
09 May 2024 16:38 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 08 May 2024 | Sale | 13,919 | 3.8213 | 53,189 | I |
09 May 2024 16:38 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 07 May 2024 | Sale | 6,025 | 3.6699 | 22,111 | I |
01 May 2024 18:16 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 01 May 2024 | Sale | 33,061 | 3.3018 | 109,161 | I |
01 May 2024 18:16 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 30 Apr 2024 | Sale | 20,535 | 3.1157 | 63,981 | I |
01 May 2024 18:16 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 29 Apr 2024 | Sale | 6,403 | 3.2473 | 20,792 | I |
24 Apr 2024 17:50 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 24 Apr 2024 | Sale | 8,064 | 3.5033 | 28,251 | I |
24 Apr 2024 17:50 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 23 Apr 2024 | Sale | 22,000 | 3.4909 | 76,800 | I |
24 Apr 2024 17:50 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 22 Apr 2024 | Sale | 14,331 | 3.5306 | 50,597 | I |
18 Apr 2024 17:00 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 17 Apr 2024 | Sale | 22,737 | 3.7131 | 84,425 | I |
18 Apr 2024 17:00 | GNLX | GENELUX Corp | SZALAY ALADAR | 10% | 16 Apr 2024 | Sale | 48,683 | 3.529 | 171,802 | I |
30 Aug 2023 19:22 | GNLX | GENELUX Corp | YU YONG | VP, Clinical Trial Operations | 30 Aug 2023 | Sale | 19,800 | 24.7 | 489,060 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)